9-ING-41 in Patients With Advanced Cancers

ABSTRACT: GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.

DISEASE(S): Resistant Cancer,Pancreatic Adenocarcinoma,Malignant Solid Tumor,Neoplasm Of Bone,Precursor T-cell Lymphoblastic Leukemia-lymphoma,Refractory Hematologic Malignancies Or Solid Tumors,Breast Neoplasms,Lung Neoplasms,Neoplasms,Bone Neoplasm,Pancreas Cancer,Neoplasm Metastasis,Malignant Glioma,Refractory Cancer,Renal Cancer,Colorectal Neoplasms,Pancreatic Neoplasms,Neoplasms Pancreatic,Acute T Cell Leukemia Lymphoma,Leukemia, T-cell,Kidney Neoplasms,Refractory Neoplasm,Refractory Non-hodgkin Lymphoma,Neoplasm, Breast,Sarcoma,Neoplasms,colorectal,Pancreatic Cancer,Lymphoma,Bone Neoplasms,Bone Cancer,Neoplasm Of Lung,Haematological Malignancy,Malignancies,Glioma,Malignancies Multiple,Bone Metastases,Cancer

PROVIDER: 2284734 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR